Maximus, Inc. (MMS) Downgraded by BidaskClub to “Sell”

Maximus, Inc. (NYSE:MMS) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Monday, July 24th.

Other equities analysts also recently issued reports about the company. Canaccord Genuity downgraded Maximus from a “buy” rating to a “hold” rating and set a $62.00 target price for the company. in a research report on Tuesday, July 4th. Jefferies Group LLC downgraded Maximus from a “buy” rating to a “hold” rating and raised their price objective for the stock from $63.00 to $64.00 in a research report on Friday, May 5th. ValuEngine downgraded Maximus from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. Maxim Group downgraded Maximus from a “buy” rating to a “hold” rating and set a $66.00 price objective for the company. in a research report on Thursday, May 4th. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded Maximus from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $62.17.

Shares of Maximus (NYSE:MMS) traded up 1.02% on Monday, hitting $60.83. The company’s stock had a trading volume of 310,118 shares. Maximus has a 52 week low of $43.69 and a 52 week high of $64.97. The firm has a market cap of $3.95 billion, a price-to-earnings ratio of 19.50 and a beta of 1.39. The stock’s 50-day moving average price is $61.19 and its 200-day moving average price is $60.86.

Maximus (NYSE:MMS) last posted its earnings results on Thursday, August 3rd. The health services provider reported $0.79 EPS for the quarter, beating the consensus estimate of $0.76 by $0.03. The firm had revenue of $600.40 million during the quarter, compared to the consensus estimate of $614.12 million. Maximus had a return on equity of 25.08% and a net margin of 8.43%. The business’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period last year, the company earned $0.79 earnings per share. Equities analysts expect that Maximus will post $3.12 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Maximus, Inc. (MMS) Downgraded by BidaskClub to “Sell”” was first reported by Stock Observer and is owned by of Stock Observer. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.thestockobserver.com/2017/08/12/maximus-inc-mms-downgraded-by-bidaskclub-updated-updated.html.

In related news, insider Mark Andrekovich sold 8,939 shares of Maximus stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $64.01, for a total transaction of $572,185.39. Following the transaction, the insider now owns 24,583 shares of the company’s stock, valued at $1,573,557.83. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel David Francis sold 1,000 shares of Maximus stock in a transaction that occurred on Friday, June 2nd. The shares were sold at an average price of $62.70, for a total value of $62,700.00. Following the transaction, the general counsel now directly owns 17,715 shares in the company, valued at approximately $1,110,730.50. The disclosure for this sale can be found here. Insiders sold 99,439 shares of company stock valued at $6,215,325 in the last three months. Insiders own 3.10% of the company’s stock.

A number of hedge funds have recently modified their holdings of the company. Neuburgh Advisers LLC raised its stake in shares of Maximus by 1.9% in the first quarter. Neuburgh Advisers LLC now owns 1,696 shares of the health services provider’s stock worth $105,000 after buying an additional 32 shares during the period. Acrospire Investment Management LLC raised its stake in shares of Maximus by 183.3% in the first quarter. Acrospire Investment Management LLC now owns 1,700 shares of the health services provider’s stock worth $106,000 after buying an additional 1,100 shares during the period. Glen Harbor Capital Management LLC raised its stake in shares of Maximus by 1.9% in the first quarter. Glen Harbor Capital Management LLC now owns 2,332 shares of the health services provider’s stock worth $145,000 after buying an additional 44 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Maximus by 10.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,367 shares of the health services provider’s stock worth $148,000 after buying an additional 220 shares during the period. Finally, First Bank & Trust raised its stake in shares of Maximus by 4.2% in the second quarter. First Bank & Trust now owns 2,507 shares of the health services provider’s stock worth $157,000 after buying an additional 101 shares during the period. Institutional investors and hedge funds own 97.89% of the company’s stock.

Maximus Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Analyst Recommendations for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply